Kedudukan dalam Saham
#24450
Based in Oslo, Norway, Lytix Biopharma ASA is a clinical-stage biotechnology... Based in Oslo, Norway, Lytix Biopharma ASA is a clinical-stage biotechnology firm dedicated to advancing innovative immunotherapies for cancer treatment. Its primary drug candidate, LTX-315, is an oncolytic molecule currently undergoing Phase II clinical trials. This therapy is formulated for intratumoral injection, aiming to provide localized treatment for solid tumors. Additionally, Lytix Biopharma is developing LTX-401, another oncolytic molecule in its preclinical phase, specifically designed to target deep-seated cancerous lesions, including those found in liver cancer. The company was established in 2003.
Perubahan (1 tahun)
-12.06%
Perdagangan Lytix Biopharma AS (LYTIX)
Harga LYTIX dengan permodalan pasaran b
Modal pasaran bagi Lytix Biopharma AS(LYTIX)
Modal Pasaran: $60.45M
Sehingga August 2026, Lytix Biopharma AS mempunyai modal pasaran sebanyak $60.45M. Ini menjadikan Lytix Biopharma AS syarikat ke-24450th paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran Lytix Biopharma AS dari 2021 hingga 2026
LYTIX berbanding dengan 5 teratas yang paling popular stocks
| Harga LYTIX |
|
Aset B |
Pasaran B |
Hasilnya |
|
|
|
|
$5.221T
|
+8,636,190.89%
|
|
|
|
|
$4.535T
|
+7,500,978.09%
|
|
|
|
|
$4.148T
|
+6,861,276.08%
|
|
|
|
|
$3.586T
|
+5,931,515.58%
|
|
|
|
|
$2.780T
|
+4,598,140.55%
|
